CHICAGO – In what ASCO expert John Heymach described as a "watershed moment" for people with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC), phase III findings from a trial testing the newer ALK inhibitor Alecensa (alectinib, Roche Holding AG) against standard-of-care Xalkori (crizotinib, Pfizer Inc.) showed that the former stopped tumor growth for a median of 15 months longer and caused fewer side effects.